Ionis Pharmaceuticals (IONS) Tops Q4 EPS by 35c, Revenues Beat; Offers FY20 Revenue Outlook Below Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St futures rise as AI stocks rally, crude prices fall
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Streamflation drives 39% of Americans to cancel streaming in 6 months
Akcea Therapeutics to Present at the Cowen 40th Annual Health Care Conference
February 26, 2020 7:01 AM ESTBOSTON, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with serious and rare diseases, today announced that Damien McDevitt, Interim CEO, will present at the Cowen 40th Annual Health Care Conference in Boston on Tuesday, March 3, 2020 at 10:40 a.m. ET.
The above listed date is subject to change. Details on presentation times or changes to presentation dates can be found on the Companys website. Please check... More
